NO332992B1 - Disintegreringsmidler for torrpulverinhalatorer og inhalator - Google Patents

Disintegreringsmidler for torrpulverinhalatorer og inhalator

Info

Publication number: NO332992B1
Authority: NO; Norway
Prior art keywords: chamber; particles; air; carrier; channel
Prior art date: 2001-06-22

Application number

NO20035654A

Other languages

English (en)

Norwegian (no)

Other versions

NO20035654L (no

NO20035654D0 (no

Inventor

Henderik Willem Frijlink

Doetie GJALTEMA

Paul Hagedoorn

Joachim Goede

Anne H De Boer

Original Assignee

Almirall Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-22

Filing date

2003-12-17

Publication date

2013-02-11

2003-12-17 Application filed by Almirall Sa filed Critical Almirall Sa

2003-12-17 Publication of NO20035654D0 publication Critical patent/NO20035654D0/no

2004-02-18 Publication of NO20035654L publication Critical patent/NO20035654L/no

2013-02-11 Publication of NO332992B1 publication Critical patent/NO332992B1/no

Links

239000000843 powder Substances 0.000 title claims abstract description 150
239000007884 disintegrant Substances 0.000 title claims abstract description 21
239000002245 particle Substances 0.000 claims abstract description 260
239000000203 mixture Substances 0.000 claims abstract description 109
238000009472 formulation Methods 0.000 claims abstract description 35
229940079593 drug Drugs 0.000 claims description 105
239000003814 drug Substances 0.000 claims description 105
239000010419 fine particle Substances 0.000 claims description 70
239000008188 pellet Substances 0.000 claims description 64
230000003434 inspiratory effect Effects 0.000 claims description 35
230000000694 effects Effects 0.000 claims description 32
230000008021 deposition Effects 0.000 claims description 24
230000033001 locomotion Effects 0.000 claims description 16
230000002829 reductive effect Effects 0.000 claims description 16
238000009826 distribution Methods 0.000 claims description 15
239000000443 aerosol Substances 0.000 claims description 14
239000003795 chemical substances by application Substances 0.000 claims description 14
230000036961 partial effect Effects 0.000 claims description 13
230000014759 maintenance of location Effects 0.000 claims description 12
230000001133 acceleration Effects 0.000 claims description 10
229940112141 dry powder inhaler Drugs 0.000 claims description 10
230000000717 retained effect Effects 0.000 claims description 10
230000009471 action Effects 0.000 claims description 7
230000004888 barrier function Effects 0.000 claims description 7
238000003860 storage Methods 0.000 claims description 6
238000013459 approach Methods 0.000 claims description 4
239000012798 spherical particle Substances 0.000 claims description 3
239000003570 air Substances 0.000 description 164
239000000853 adhesive Substances 0.000 description 48
230000001070 adhesive effect Effects 0.000 description 48
239000013078 crystal Substances 0.000 description 43
238000000151 deposition Methods 0.000 description 24
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 22
229960001375 lactose Drugs 0.000 description 22
239000008101 lactose Substances 0.000 description 22
238000002156 mixing Methods 0.000 description 22
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 21
239000002775 capsule Substances 0.000 description 21
238000010276 construction Methods 0.000 description 16
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 15
239000012876 carrier material Substances 0.000 description 15
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 12
238000000034 method Methods 0.000 description 12
238000000926 separation method Methods 0.000 description 12
229960004436 budesonide Drugs 0.000 description 11
230000003993 interaction Effects 0.000 description 11
210000000214 mouth Anatomy 0.000 description 11
238000010586 diagram Methods 0.000 description 10
239000006185 dispersion Substances 0.000 description 10
238000012986 modification Methods 0.000 description 10
230000004048 modification Effects 0.000 description 10
239000000546 pharmaceutical excipient Substances 0.000 description 10
210000002345 respiratory system Anatomy 0.000 description 10
230000008901 benefit Effects 0.000 description 9
238000013461 design Methods 0.000 description 9
230000035508 accumulation Effects 0.000 description 8
238000009825 accumulation Methods 0.000 description 8
238000011068 loading method Methods 0.000 description 8
238000005259 measurement Methods 0.000 description 7
230000009467 reduction Effects 0.000 description 7
230000007423 decrease Effects 0.000 description 6
230000003247 decreasing effect Effects 0.000 description 6
238000011049 filling Methods 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
239000011164 primary particle Substances 0.000 description 6
108010078777 Colistin Proteins 0.000 description 5
230000002776 aggregation Effects 0.000 description 5
239000000969 carrier Substances 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
239000012634 fragment Substances 0.000 description 5
235000019592 roughness Nutrition 0.000 description 5
230000007704 transition Effects 0.000 description 5
230000001464 adherent effect Effects 0.000 description 4
238000005054 agglomeration Methods 0.000 description 4
230000008859 change Effects 0.000 description 4
229960001127 colistin sulfate Drugs 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
230000005484 gravity Effects 0.000 description 4
230000001788 irregular Effects 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
ZESIAEVDVPWEKB-ORCFLVBFSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O ZESIAEVDVPWEKB-ORCFLVBFSA-N 0.000 description 4
230000021715 photosynthesis, light harvesting Effects 0.000 description 4
238000010408 sweeping Methods 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
239000013543 active substance Substances 0.000 description 3
238000012387 aerosolization Methods 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
238000004140 cleaning Methods 0.000 description 3
239000011362 coarse particle Substances 0.000 description 3
230000007547 defect Effects 0.000 description 3
238000005265 energy consumption Methods 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
239000008187 granular material Substances 0.000 description 3
238000000227 grinding Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000010354 integration Effects 0.000 description 3
238000005457 optimization Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
238000010008 shearing Methods 0.000 description 3
125000006850 spacer group Chemical group 0.000 description 3
230000003746 surface roughness Effects 0.000 description 3
238000012360 testing method Methods 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
241000222122 Candida albicans Species 0.000 description 2
206010007134 Candida infections Diseases 0.000 description 2
241000276498 Pollachius virens Species 0.000 description 2
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
238000005411 Van der Waals force Methods 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000002411 adverse Effects 0.000 description 2
BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 2
201000003984 candidiasis Diseases 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
230000001276 controlling effect Effects 0.000 description 2
238000012937 correction Methods 0.000 description 2
238000005520 cutting process Methods 0.000 description 2
238000002050 diffraction method Methods 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000007689 inspection Methods 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000000463 material Substances 0.000 description 2
WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 2
239000011148 porous material Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
238000005096 rolling process Methods 0.000 description 2
238000007790 scraping Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
208000032953 Device battery issue Diseases 0.000 description 1
206010013952 Dysphonia Diseases 0.000 description 1
208000010473 Hoarseness Diseases 0.000 description 1
OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
206010067171 Regurgitation Diseases 0.000 description 1
244000007853 Sarothamnus scoparius Species 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
241001126918 Sycon Species 0.000 description 1
239000005862 Whey Substances 0.000 description 1
102000007544 Whey Proteins Human genes 0.000 description 1
108010046377 Whey Proteins Proteins 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
239000012080 ambient air Substances 0.000 description 1
239000003831 antifriction material Substances 0.000 description 1
229940053670 asmanex Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
229960003346 colistin Drugs 0.000 description 1
239000002131 composite material Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
239000004020 conductor Substances 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
229960000265 cromoglicic acid Drugs 0.000 description 1
IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000001595 flow curve Methods 0.000 description 1
WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
229960000289 fluticasone propionate Drugs 0.000 description 1
239000011888 foil Substances 0.000 description 1
229940107791 foradil Drugs 0.000 description 1
BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000007373 indentation Methods 0.000 description 1
238000011044 inertial separation Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000000622 irritating effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
235000005772 leucine Nutrition 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229960002744 mometasone furoate Drugs 0.000 description 1
JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
230000006911 nucleation Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000003300 oropharynx Anatomy 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical class C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000006069 physical mixture Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
229960004583 pranlukast Drugs 0.000 description 1
UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
229940072266 pulmicort Drugs 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000004202 respiratory function Effects 0.000 description 1
238000007142 ring opening reaction Methods 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
229960005018 salmeterol xinafoate Drugs 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
229940090585 serevent Drugs 0.000 description 1
230000035939 shock Effects 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
239000011343 solid material Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
238000004544 sputter deposition Methods 0.000 description 1
238000004808 supercritical fluid chromatography Methods 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000002344 surface layer Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
229930195727 α-lactose Natural products 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0086—Inhalation chambers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/001—Particle size control
- A61M11/002—Particle size control by flow deviation causing inertial separation of transported particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2206/00—Characteristics of a physical parameter; associated device therefor
- A61M2206/10—Flow characteristics
- A61M2206/16—Rotating swirling helical flow, e.g. by tangential inflows

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Anesthesiology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Pulmonology (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)
Detergent Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20035654A 2001-06-22 2003-12-17 Disintegreringsmidler for torrpulverinhalatorer og inhalator NO332992B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10129703A DE10129703A1 (de)	2001-06-22	2001-06-22	Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
PCT/EP2002/006610 WO2003000325A1 (fr)	2001-06-22	2002-06-15	Systeme de desintegration de formulation de poudre et procede pour inhalateurs de poudre seche

Publications (3)

Publication Number	Publication Date
NO20035654D0 NO20035654D0 (no)	2003-12-17
NO20035654L NO20035654L (no)	2004-02-18
NO332992B1 true NO332992B1 (no)	2013-02-11

Family

ID=7688810

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20035654A NO332992B1 (no)	2001-06-22	2003-12-17	Disintegreringsmidler for torrpulverinhalatorer og inhalator

Country Status (30)

Country	Link
EP (1)	EP1397174B1 (fr)
JP (1)	JP4116537B2 (fr)
KR (1)	KR100904955B1 (fr)
CN (1)	CN100337699C (fr)
AR (1)	AR034616A1 (fr)
AT (1)	ATE477826T1 (fr)
AU (1)	AU2009200071B2 (fr)
BG (1)	BG66589B1 (fr)
BR (2)	BRPI0210026B8 (fr)
CA (1)	CA2445892C (fr)
CY (1)	CY1110924T1 (fr)
CZ (1)	CZ302528B6 (fr)
DE (2)	DE10129703A1 (fr)
DK (1)	DK1397174T3 (fr)
ES (1)	ES2350973T3 (fr)
HR (1)	HRP20040058B1 (fr)
HU (1)	HU227457B1 (fr)
IL (3)	IL158614A0 (fr)
MX (1)	MXPA03011550A (fr)
NO (1)	NO332992B1 (fr)
NZ (1)	NZ530308A (fr)
PL (1)	PL204900B1 (fr)
PT (1)	PT1397174E (fr)
RU (1)	RU2291717C2 (fr)
SI (1)	SI1397174T1 (fr)
SK (1)	SK288034B6 (fr)
TW (1)	TW567075B (fr)
UA (1)	UA74648C2 (fr)
WO (1)	WO2003000325A1 (fr)
ZA (1)	ZA200308555B (fr)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2165768B1 (es)	1999-07-14	2003-04-01	Almirall Prodesfarma Sa	Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
EP1488819A1 (fr)	2003-06-16	2004-12-22	Rijksuniversiteit te Groningen	Inhalateur de poudre sèche et procédé d'inhalation pulmonaire de poudre sèche
RU2258539C1 (ru) *	2004-03-23	2005-08-20	Чучалин Александр Григорьевич	Порошковый ингалятор
ES2265276B1 (es)	2005-05-20	2008-02-01	Laboratorios Almirall S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
DE102005046645B3 (de) *	2005-09-29	2006-07-20	Braunform Gmbh	Pulverinhalator
DE102005046644B3 (de) *	2005-09-29	2006-07-20	Braunform Gmbh	Pulverinhalator
DE102006007495A1 (de)	2006-02-17	2007-08-23	Siegfried Generics International Ag	Dispergiereinheit
JP2009533104A (ja) *	2006-04-13	2009-09-17	ベーリンガーインゲルハイムマイクロパーツゲゼルシャフトミットベシュレンクテルハフツング	計量投与器具
ES2319596B1 (es)	2006-12-22	2010-02-08	Laboratorios Almirall S.A.	Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
ES2320955B1 (es)	2007-03-02	2010-03-16	Laboratorios Almirall S.A.	Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
ES2569359T3 (es) *	2007-07-06	2016-05-10	Vectura Delivery Devices Limited	Inhalador
EP2020249A1 (fr)	2007-08-01	2009-02-04	Boehringer Ingelheim Pharma GmbH & Co. KG	Inhalateur
UY31272A1 (es)	2007-08-10	2009-01-30	Almirall Lab	Nuevos derivados de ácido azabifenilaminobenzoico
DE102007041720A1 (de) *	2007-09-04	2009-03-05	Alfred Von Schuckmann	Vorrichtung zur Darreichung eines blisterverpackten Medikaments
US8439033B2 (en) *	2007-10-09	2013-05-14	Microdose Therapeutx, Inc.	Inhalation device
EP2534957B1 (fr)	2007-12-14	2015-05-27	AeroDesigns, Inc	Administration de produits sous forme d'aérosols
EP2082764A1 (fr) *	2008-01-24	2009-07-29	Boehringer Ingelheim International GmbH	Inhalateur
ES2546025T3 (es)	2008-01-24	2015-09-17	Vectura Delivery Devices Limited	Inhalador
EP2100599A1 (fr)	2008-03-13	2009-09-16	Laboratorios Almirall, S.A.	Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP2100598A1 (fr) *	2008-03-13	2009-09-16	Laboratorios Almirall, S.A.	Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP2108641A1 (fr)	2008-04-11	2009-10-14	Laboratorios Almirall, S.A.	Nouveaux dérivés substitués de spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one et leur utilisation comme ihibiteurs de p38 mitogen-activated kinase
EP2113503A1 (fr)	2008-04-28	2009-11-04	Laboratorios Almirall, S.A.	Nouveaux dérivés d'indolin-2-one substitués et leur utilisation comme inhibiteurs de p38 mitogen-activated kinase
ES2614888T3 (es) *	2008-05-23	2017-06-02	Otsuka Techno Corporation	Inhalador de polvo
EP2135610A1 (fr)	2008-06-20	2009-12-23	Laboratorios Almirall, S.A.	Combinaison comportant des inhibiteurs DHODH et de la méthotrexate
EP2177521A1 (fr)	2008-10-14	2010-04-21	Almirall, S.A.	Nouveaux dérivés de 2-amidothiadiazole
EP2196465A1 (fr)	2008-12-15	2010-06-16	Almirall, S.A.	Dérivés de (3-oxo)pyridazin-4-ylurée comme inhibiteurs de PDE4
UY32297A (es)	2008-12-22	2010-05-31	Almirall Sa	Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2202232A1 (fr)	2008-12-26	2010-06-30	Laboratorios Almirall, S.A.	Dérivés du 1,2,4-oxadiazole et leur application thérapeutique
EP2210890A1 (fr)	2009-01-19	2010-07-28	Almirall, S.A.	Dérivés d'oxadiazoles en tant qu'agonistes du récepteur S1P1
EP2210615A1 (fr)	2009-01-21	2010-07-28	Almirall, S.A.	Combinaisons comportant des inhibiteurs DHODH et de la méthotrexate
EP2221297A1 (fr)	2009-02-18	2010-08-25	Almirall, S.A.	5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one et son utiisation dans le traitement de maladies des voies respiratoires
EP2221055A1 (fr)	2009-02-18	2010-08-25	Almirall, S.A.	5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one pour le traitement de la fonction pulmonaire
EP2226323A1 (fr)	2009-02-27	2010-09-08	Almirall, S.A.	Nouveaux dérivés de tétrahydropyrazolo [3,4-c]isoquinoléine-5-amine
MX2011009251A (es) *	2009-03-04	2011-11-18	Mannkind Corp	Sistema mejorado de suministro de farmaco en polvo seco.
EP2228368A1 (fr)	2009-03-12	2010-09-15	Almirall, S.A.	Procédé de fabrication de 5-(2-{[6-(2,2-difluoro-2-ph2nyl2thoxy)hexyl]amino}-1-hydroxy2thyl)-8-hydroxyquinolin-2(1h)-one
EP2239256A1 (fr)	2009-03-13	2010-10-13	Almirall, S.A.	Sel de sodium de l'acide 5-cyclopropyl-2-{[2-(2,6-difluorophényl)pyrimidin-5-yl]amino}benzoïque en tant qu'inhibiteurs de la DHOD
EP2305660A1 (fr)	2009-09-25	2011-04-06	Almirall, S.A.	Nouveaux dérivés de thiadiazole
EP2314577A1 (fr)	2009-10-16	2011-04-27	Almirall, S.A.	Procédé de fabrication de l'acide 2-[(3,5-difluoro-3'-méthoxy-1,1'-biphényl-4-yl)amino]nicotinique
GB0919465D0 (en) *	2009-11-06	2009-12-23	Norton Healthcare Ltd	Airflow adaptor for a breath-actuated dry powder inhaler
EP2322176A1 (fr)	2009-11-11	2011-05-18	Almirall, S.A.	Nouveaux dérivés de 7-phényl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one
AU2010319681B2 (en) *	2009-11-13	2015-12-17	Merck Sharp & Dohme Llc	Drug products, dry powder inhalers and polyflux collider arrangements
EP2343287A1 (fr)	2009-12-10	2011-07-13	Almirall, S.A.	Nouveaux dérivés de 2-aminothiadiazole
EP2338888A1 (fr)	2009-12-24	2011-06-29	Almirall, S.A.	Dérivés d'imidazopyridine en tant qu'inhibiteurs JAK
EP2360158A1 (fr)	2010-02-18	2011-08-24	Almirall, S.A.	Dérivés de pyrazole en tant qu'inhibiteurs de JAK
UY33213A (es)	2010-02-18	2011-09-30	Almirall Sa	Derivados de pirazol como inhibidores de jak
EP2366702A1 (fr)	2010-03-18	2011-09-21	Almirall, S.A.	Nouveaux dérivés d'oxadiazole
EP2380890A1 (fr)	2010-04-23	2011-10-26	Almirall, S.A.	Nouveaux dérivés de 7,8-dihydro-1,6-naphthyridin-5(6h)-one comme PDE4 inhibiteurs
EP2386555A1 (fr)	2010-05-13	2011-11-16	Almirall, S.A.	Nouveaux dérivés de cyclohéxylamine dotés d'activités agoniste bêta 2 adrénergique et antagoniste muscarinique m3
EP2390252A1 (fr)	2010-05-19	2011-11-30	Almirall, S.A.	Nouveaux dérivés de pyrazole
EP2394998A1 (fr)	2010-05-31	2011-12-14	Almirall, S.A.	Dérivés de 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl en tant qu'inhibiteurs de la PDE4
EP2397482A1 (fr)	2010-06-15	2011-12-21	Almirall, S.A.	Dérivés d'imidazolone d'hétéroaryle en tant qu'inhibiteurs de JAK
EP2441755A1 (fr)	2010-09-30	2012-04-18	Almirall, S.A.	Dérivés de pyridine et isoquinoline comme inhibiteurs des kinases Syk et JAK
EP2455081A1 (fr)	2010-11-23	2012-05-23	Almirall, S.A.	Agonistes de récepteur S1P1 à utiliser dans le traitement de la maladie de Crohn
EP2455080A1 (fr)	2010-11-23	2012-05-23	Almirall, S.A.	Agonistes de récepteur S1P1 à utiliser dans le traitement de la sclérose en plaques
EP2457900A1 (fr)	2010-11-25	2012-05-30	Almirall, S.A.	Nouveaux dérivés de pyrazole présentant un comportement antagoniste CRTH2
EP2463289A1 (fr)	2010-11-26	2012-06-13	Almirall, S.A.	Dérivés imidazo[1,2-b]pyridazine en tant qu'inhibiteur JAK
US8974450B2 (en)	2011-02-03	2015-03-10	Covidien Lp	System and method for ablation procedure monitoring using electrodes
EP2489663A1 (fr)	2011-02-16	2012-08-22	Almirall, S.A.	Composés en tant qu'inhibiteurs de la syk kinase
EP2510928A1 (fr)	2011-04-15	2012-10-17	Almirall, S.A.	Aclidinium pour l'amélioration du sommeil des patients avec des maldadies respiratoires
EP2518071A1 (fr)	2011-04-29	2012-10-31	Almirall, S.A.	Dérivés d'imidazopyridine en tant qu'inhibiteurs PI3K
EP2518070A1 (fr)	2011-04-29	2012-10-31	Almirall, S.A.	Dérivés de pyrrolotriazinon en tant qu'inhibiteurs PI3K
EP2526945A1 (fr)	2011-05-25	2012-11-28	Almirall, S.A.	Nouveaux antagonistes de CRTH2
EP2527344A1 (fr)	2011-05-25	2012-11-28	Almirall, S.A.	Dérivés de pyridin-2(1h)-one utiles comme médicaments pour le traitement de maladies myeloproliferatives, de rejets de greffe, de maladies a médiation immune et de maladies inflammatoires
EP2548863A1 (fr)	2011-07-18	2013-01-23	Almirall, S.A.	Nouveaux antagonistes de CRTH2
EP2548876A1 (fr)	2011-07-18	2013-01-23	Almirall, S.A.	Nouveaux antagonistes de CRTH2
EP2554544A1 (fr)	2011-08-01	2013-02-06	Almirall, S.A.	Dérivés de pyridin-2(1h)-one en tant qu'inhibiteurs de JAK
US9446209B2 (en)	2011-09-07	2016-09-20	Concentrx Pharmaceuticals, Inc.	Dry powder inhalation device
EP2578570A1 (fr)	2011-10-07	2013-04-10	Almirall, S.A.	Nouveau procédé de fabrication de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy)hexyl]amino}-1-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one via de nouveaux intermédiaires de synthèse
EP2592078A1 (fr)	2011-11-11	2013-05-15	Almirall, S.A.	Nouveaux dérivés de cyclohéxylamine dotés d'activités agonistes bêta 2 adrénergique et antagoniste muscarinique M3
EP2592077A1 (fr)	2011-11-11	2013-05-15	Almirall, S.A.	Nouveaux dérivés de cyclohéxylamine dotés d'activités agonistes bêta 2 adrénergique et antagoniste muscarinique M3
EP2617450A1 (fr) *	2012-01-20	2013-07-24	Almirall S.A.	Dispositif d'inhalation pour médicaments en poudre
EP2617448A1 (fr)	2012-01-20	2013-07-24	Almirall S.A.	Dispositif d'inhalation pour médicaments en poudre
EP2617449A1 (fr)	2012-01-20	2013-07-24	Almirall S.A.	Dispositif d'inhalation pour médicaments en poudre
EP2641900A1 (fr)	2012-03-20	2013-09-25	Almirall, S.A.	Nouvelles formes polymorphes de héminapadisylate de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy) hexyl]amino}-1-(R)-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one en tant qu'agoniste du récepteur adrénergique ß2
EP2647627A1 (fr)	2012-04-02	2013-10-09	Almirall, S.A.	Sels de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phényléthoxy)phényl]éthyl}amino)- 1-hydroxyéthyl]-8- hydroxyquinolin-2(1h)-one
EP2666465A1 (fr)	2012-05-25	2013-11-27	Almirall, S.A.	Nouveau dosage et formule
EP2668941A1 (fr)	2012-05-31	2013-12-04	Almirall, S.A.	Nouveau dosage et formulation d'abediterol
WO2014060431A1 (fr)	2012-10-16	2014-04-24	Almirall, S.A.	Dérivés de pyrrolotriazinone en tant qu'inhibiteurs des pi3k
EP2738172A1 (fr)	2012-11-28	2014-06-04	Almirall, S.A.	Nouveaux composés bicycliques utilisés comme modulateurs du canal crac
US20150328194A1 (en)	2012-12-17	2015-11-19	Almirall, S.A.	New use of aclidinium
MA38260B1 (fr)	2012-12-18	2018-04-30	Almirall Sa	Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
TW201446767A (zh)	2013-02-15	2014-12-16	Almirall Sa	作為磷脂肌醇3-激酶抑製劑之吡咯並三嗪衍生物
EP2848615A1 (fr)	2013-07-03	2015-03-18	Almirall, S.A.	Nouveaux dérivés de pyrazole utilisés comme modulateurs du canal CRAC
WO2015091285A1 (fr)	2013-12-19	2015-06-25	Almirall S.A.	Formulation de dosage comprenant du salmétérol et du propionate de fluticasone
EP2944343A1 (fr)	2014-05-15	2015-11-18	AstraZeneca AB	Inhalateur de poudre sèche
DK3151893T6 (da) *	2014-06-06	2022-02-07	Univ Groningen	Åndedrætsaktiveret tørpulverinhalator
KR101990017B1 (ko) *	2014-11-26	2019-06-17	벡투라 딜리버리 디바이시스 리미티드	건조 분말 흡입기
CN107427650A (zh)	2015-01-14	2017-12-01	瑞必治公司	粉末分散方法和装置
EP3286178A1 (fr)	2015-04-21	2018-02-28	Almirall S.A.	Dérivés hétérocycliques amino-substitués utilisés comme inhibiteurs des canaux sodiques
WO2016202800A1 (fr)	2015-06-16	2016-12-22	Almirall, S.A.	Dérivés de pyrrolotriazinone en tant qu'inhibiteurs de pi3k
WO2017076990A1 (fr)	2015-11-05	2017-05-11	Almirall, S.A.	Sels d'addition de n-[4-(4-{[(1s)-1-(5-méthyl-4-oxo-3-phényl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)éthyl]amino}-7h-pyrrolo[2,3-d]pyrimidin-5-yl)-1h-indol-6-yl]sulfamide
RU2634258C1 (ru) *	2016-11-08	2017-10-24	федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН)	Наполнитель для капсульного ингалятора
CN109922851B (zh) *	2016-11-30	2022-05-27	菲利普莫里斯生产公司	具有经大小设定的腔的吸入器
AU2018244582A1 (en)	2017-03-28	2019-09-19	Concentrx Pharmaceuticals, Inc.	Devices and methods for delivering dry powder medicaments
CN107123354B (zh) *	2017-05-21	2019-03-19	谭淞文	分选花形微粒载体的吸入器、呼吸道及肺部模型设备集成
TW201919682A (zh)	2017-08-08	2019-06-01	西班牙商阿爾米雷爾有限公司	活化Ｎｒｆ２路徑的新穎化合物
US12496413B2 (en) *	2018-02-19	2025-12-16	Philip Morris Products S.A.	Dry powder inhaler
CN110201281B (zh) *	2018-02-28	2021-08-06	张江	吸入给药装置和吸入给药组合结构
CN110201278B (zh) *	2018-02-28	2021-07-30	张江	用于吸入给药的药盒和吸入给药组合结构
CN110201279B (zh) *	2018-02-28	2021-05-11	张江	用于吸入给药的药盒和吸入给药组合结构
CN110201280B (zh) *	2018-02-28	2021-07-30	张江	用于吸入给药装置的吸嘴和吸入给药装置
CN111514418B (zh) *	2019-06-12	2022-01-14	中南大学湘雅二医院	一种自吸式经鼻粉末材料给送装置
CN111359060A (zh) *	2020-02-20	2020-07-03	深圳麦克韦尔科技有限公司	雾化吸嘴及雾化装置
US12117379B2 (en) *	2020-05-15	2024-10-15	Horiba, Ltd.	Sample dispersing device and sample dispersing method
CN112030136B (zh) *	2020-09-01	2024-12-27	江苏微导纳米科技股份有限公司	镀膜腔体及粉末镀膜装置
CN113750331B (zh) *	2021-08-18	2022-08-16	华中科技大学	一种干粉吸入器
CN114632235B (zh) *	2022-03-04	2023-04-25	华中科技大学	一种干粉吸入器
CN115006656A (zh) *	2022-05-18	2022-09-06	苏州易合医药有限公司	一种可连续提供肺部活性剂粉雾剂的给药装置
CN117547693B (zh) *	2023-12-20	2025-08-01	上海新黄河制药有限公司	一种适用于双储库粉雾剂装置的流道
CN118575973B (zh) *	2024-06-27	2025-11-21	黑龙江飞鹤乳业有限公司	压缩食品粉末的制备方法及制备压缩食品的方法
CN118592629B (zh) *	2024-07-01	2026-01-02	广西瀛开科技有限公司	一种坚果粘壳分离装置
WO2026078074A1 (fr) *	2024-10-09	2026-04-16	Vectura Delivery Devices Limited	Inhalateur à poudre sèche
WO2026078086A1 (fr) *	2024-10-09	2026-04-16	Vectura Delivery Devices Limited	Inhalateur de poudre sèche

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1478138A (en) *	1973-07-18	1977-06-29	Beecham Group Ltd	Device for the administration of powders
IT7920688U1 (it)	1979-02-05	1980-08-05	Chiesi Paolo	Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore
DE3274065D1 (de)	1981-07-08	1986-12-11	Draco Ab	Powder inhalator
US4570630A (en)	1983-08-03	1986-02-18	Miles Laboratories, Inc.	Medicament inhalation device
DE3927170A1 (de)	1989-08-17	1991-02-21	Boehringer Ingelheim Kg	Inhalator
IT1237118B (it)	1989-10-27	1993-05-18	Miat Spa	Inalatore multidose per farmaci in polvere.
NZ250988A (en) *	1990-06-14	1995-09-26	Rhone Poulenc Rorer Ltd	Powder inhaler: swirling chamber with anti-static walls
WO1992003175A1 (fr)	1990-08-11	1992-03-05	Fisons Plc	Dispositif d'inhalation
US5492112A (en) *	1991-05-20	1996-02-20	Dura Pharmaceuticals, Inc.	Dry powder inhaler
DE4211475A1 (de) *	1991-12-14	1993-06-17	Asta Medica Ag	Pulverinhalator
DE4239402A1 (de) *	1992-11-24	1994-05-26	Bayer Ag	Pulverinhalator
DK0674533T3 (da)	1992-12-18	1999-09-27	Schering Corp	Inhalator for medikamenter i pulverform
PL179126B1 (en) *	1994-10-04	2000-07-31	Procter & Gamble	Method of and apparatus for electrostatically atomising solid particles
DE19522416C2 (de) *	1995-06-21	2003-11-20	Sofotec Gmbh & Co Kg	Vorrichtung zum Dispergieren von Pulver in einem Luftstrom zur Verwendung mit Pulver-Inhalatoren
ATE209518T1 (de) *	1995-06-21	2001-12-15	Asta Medica Ag	Arzneipulverkartusche mit integrierter dosiereinrichtung, sowie pulverinhalator
FR2738153B1 (fr) *	1995-09-04	1998-01-02	Valois	Appareil d'inhalation destine a distribuer des doses precises et reproductibles de produit pulverulent
EP1129705A1 (fr) *	2000-02-17	2001-09-05	Rijksuniversiteit te Groningen	Formulation en poudre pour inhalation

2001
- 2001-06-22 DE DE10129703A patent/DE10129703A1/de not_active Withdrawn
2002
- 2002-06-12 TW TW091112804A patent/TW567075B/zh not_active IP Right Cessation
- 2002-06-15 KR KR1020037016628A patent/KR100904955B1/ko not_active Expired - Lifetime
- 2002-06-15 WO PCT/EP2002/006610 patent/WO2003000325A1/fr not_active Ceased
- 2002-06-15 JP JP2003506966A patent/JP4116537B2/ja not_active Expired - Lifetime
- 2002-06-15 BR BRPI0210026A patent/BRPI0210026B8/pt not_active IP Right Cessation
- 2002-06-15 IL IL15861402A patent/IL158614A0/xx unknown
- 2002-06-15 SK SK27-2004A patent/SK288034B6/sk unknown
- 2002-06-15 HR HRP20040058AA patent/HRP20040058B1/hr not_active IP Right Cessation
- 2002-06-15 DE DE60237366T patent/DE60237366D1/de not_active Expired - Lifetime
- 2002-06-15 SI SI200230925T patent/SI1397174T1/sl unknown
- 2002-06-15 PT PT02780833T patent/PT1397174E/pt unknown
- 2002-06-15 CN CNB02812121XA patent/CN100337699C/zh not_active Expired - Lifetime
- 2002-06-15 HU HU0400212A patent/HU227457B1/hu unknown
- 2002-06-15 ES ES02780833T patent/ES2350973T3/es not_active Expired - Lifetime
- 2002-06-15 BR BR0210026-6A patent/BR0210026A/pt active IP Right Grant
- 2002-06-15 NZ NZ530308A patent/NZ530308A/en not_active IP Right Cessation
- 2002-06-15 CZ CZ20040046A patent/CZ302528B6/cs not_active IP Right Cessation
- 2002-06-15 DK DK02780833.6T patent/DK1397174T3/da active
- 2002-06-15 EP EP02780833A patent/EP1397174B1/fr not_active Expired - Lifetime
- 2002-06-15 RU RU2004102037/14A patent/RU2291717C2/ru active
- 2002-06-15 PL PL365946A patent/PL204900B1/pl unknown
- 2002-06-15 MX MXPA03011550A patent/MXPA03011550A/es active IP Right Grant
- 2002-06-15 AT AT02780833T patent/ATE477826T1/de active
- 2002-06-15 UA UA20031211618A patent/UA74648C2/uk unknown
- 2002-06-15 CA CA2445892A patent/CA2445892C/fr not_active Expired - Lifetime
- 2002-06-21 AR ARP020102359A patent/AR034616A1/es active IP Right Grant
2003
- 2003-10-27 IL IL158614A patent/IL158614A/en active IP Right Grant
- 2003-11-03 ZA ZA200308555A patent/ZA200308555B/en unknown
- 2003-12-17 NO NO20035654A patent/NO332992B1/no not_active IP Right Cessation
2004
- 2004-01-06 BG BG108512A patent/BG66589B1/bg unknown
2009
- 2009-01-08 AU AU2009200071A patent/AU2009200071B2/en not_active Expired
2010
- 2010-11-17 CY CY20101101039T patent/CY1110924T1/el unknown
2011
- 2011-02-01 IL IL210983A patent/IL210983A/en active IP Right Grant

Also Published As

Publication number	Publication date
UA74648C2 (en)	2006-01-16
IL210983A0 (en)	2011-04-28
IL158614A (en)	2012-12-31
RU2291717C2 (ru)	2007-01-20
CZ200446A3 (cs)	2005-02-16
KR100904955B1 (ko)	2009-06-26
HUP0400212A2 (en)	2004-06-28
KR20040039203A (ko)	2004-05-10
CZ302528B6 (cs)	2011-07-07
CA2445892C (fr)	2010-08-10
MXPA03011550A (es)	2004-03-18
DE10129703A1 (de)	2003-01-02
NZ530308A (en)	2007-01-26
AR034616A1 (es)	2004-03-03
CN1541125A (zh)	2004-10-27
TW567075B (en)	2003-12-21
PL365946A1 (en)	2005-01-24
SK288034B6 (en)	2013-01-02
CN100337699C (zh)	2007-09-19
IL158614A0 (en)	2004-05-12
ES2350973T3 (es)	2011-01-28
ATE477826T1 (de)	2010-09-15
BRPI0210026B8 (pt)	2021-06-22
PL204900B1 (pl)	2010-02-26
WO2003000325A1 (fr)	2003-01-03
BG66589B1 (bg)	2017-07-31
HU227457B1 (en)	2011-06-28
BRPI0210026B1 (pt)	2018-04-03
AU2009200071A1 (en)	2009-02-05
CY1110924T1 (el)	2015-06-10
BG108512A (en)	2005-02-28
IL210983A (en)	2014-11-30
JP4116537B2 (ja)	2008-07-09
SK272004A3 (sk)	2005-10-06
RU2004102037A (ru)	2005-05-27
JP2004530498A (ja)	2004-10-07
ZA200308555B (en)	2004-02-17
HRP20040058A2 (en)	2004-08-31
SI1397174T1 (sl)	2010-12-31
CA2445892A1 (fr)	2003-01-03
BR0210026A (pt)	2004-04-13
NO20035654L (no)	2004-02-18
HK1064313A1 (en)	2005-01-28
EP1397174A1 (fr)	2004-03-17
DK1397174T3 (da)	2010-12-06
AU2009200071B2 (en)	2011-07-07
NO20035654D0 (no)	2003-12-17
HRP20040058B1 (hr)	2015-02-27
PT1397174E (pt)	2010-11-10
EP1397174B1 (fr)	2010-08-18
DE60237366D1 (de)	2010-09-30

Legal Events

Date	Code	Title	Description
2015-08-24	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: ASTRAZENECA AB, SE
2018-01-22	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO332992B1 (no)	2013-02-11	Disintegreringsmidler for torrpulverinhalatorer og inhalator
US6681768B2 (en)	2004-01-27	Powder formulation disintegrating system and method for dry powder inhalers
US7344734B2 (en)	2008-03-18	Powder formulation
JP5705112B2 (ja)	2015-04-22	ドライパウダー吸入エアロゾル用の大径キャリア粒子を含む製剤
De Boer et al.	2006	Air classifier technology (ACT) in dry powder inhalation: Part 4. Performance of air classifier technology in the Novolizer® multi-dose dry powder inhaler
De Boer et al.	2006	Air classifier technology (ACT) in dry powder inhalation: Part 3. Design and development of an air classifier family for the Novolizer® multi-dose dry powder inhaler
KR102452773B1 (ko)	2022-10-11	흡입용 의약 조성물
AU2002350483A1 (en)	2003-01-08	Powder formulation disintegrating system and method for dry powder
HK1064313B (en)	2010-11-12	Powder formulation disintegrating system and dry powder inhalers